Balyasny Asset Management LLC Karyopharm Therapeutics Inc. Transaction History

Balyasny Asset Management LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.87 - $1.58 $19,628 - $35,647	22,562 New	22,562 $19,000
Q4 2022 Feb 14, 2023	SELL	$2.48 - $5.93 $1.45 Million - $3.46 Million	-583,309 Reduced 97.94%	12,249 $41,000
Q3 2022 Nov 14, 2022	BUY	$4.08 - $5.82 $2.08 Million - $2.97 Million	509,499 Added 592.03%	595,558 $3.25 Million
Q2 2022 Aug 15, 2022	SELL	$4.15 - $8.37 $1.06 Million - $2.15 Million	-256,425 Reduced 74.87%	86,059 $388,000
Q1 2022 May 16, 2022	BUY	$5.91 - $14.38 $2.02 Million - $4.92 Million	342,484 New	342,484 $2.52 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $8.61 $1.04 Million - $1.73 Million	-200,412 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.45 - $10.63 $670,895 - $1.6 Million	150,763 Added 303.66%	200,412 $1.17 Million
Q2 2021 Aug 16, 2021	SELL	$8.11 - $11.11 $1.96 Million - $2.68 Million	-241,538 Reduced 82.95%	49,649 $512,000
Q1 2021 May 17, 2021	SELL	$9.85 - $17.69 $702,482 - $1.26 Million	-71,318 Reduced 19.67%	291,187 $3.06 Million
Q4 2020 Feb 16, 2021	BUY	$14.15 - $17.19 $5.13 Million - $6.23 Million	362,505 New	362,505 $5.61 Million
Q3 2020 Nov 16, 2020	SELL	$14.14 - $19.71 $3.15 Million - $4.4 Million	-223,043 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.6 - $25.25 $3.7 Million - $5.63 Million	223,043 New	223,043 $4.22 Million
Q1 2019 May 15, 2019	SELL	$4.12 - $10.25 $170,835 - $425,016	-41,465 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.2 - $16.95 $31,200 - $64,494	3,805 Added 10.1%	41,465 $389,000
Q3 2018 Nov 14, 2018	BUY	$17.03 - $21.18 $641,349 - $797,638	37,660 New	37,660 $641,000

57.6M

258K

81.2K

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $53.5M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.